---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-068304"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:31:51.888697+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari closes ~$7.6M private placement of ADSs and warrants

## Summary
- Sold 3,817,553 ADSs and warrants at $1.885/unit to investors including chairman and interim CEO; 212,201 units to close later.
- Warrants exercisable for 3 years at $1.76/ADS; insider warrants at $1.79/ADS.
- Paid Paulson Investment Co. 8% cash fee and issued placement agent warrants for 332,380 ADSs at $1.885, 5-year term.
- Company to file resale registration statement with SEC by June 28, 2024.
- Securities issued under Section 4(a)(2) and Regulation D; accredited investors only.

## SEC filing metadata
- accession: 0000950170-24-068304
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/0000950170-24-068304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/aktx-20240529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-068304
- JSON: https://secwatch.observer/filing/0000950170-24-068304.json
- Plain text: https://secwatch.observer/filing/0000950170-24-068304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.